Neurocentrx Pharma, an Edinburgh, Scotland, UK-based clinical-stage biopharmaceutical company, closed its seed extension funding. It included an award of over $5M investment from the Wellcome Trust. The company intends to use the funds to accelerate its clinical development programs. Neurocentrx leverages clinical experts and global clinical research to accelerate its product development programs, targeting severe mood disorders that are poorly addressed by other treatments. Initially focusing on TR-MDD and TR-BPD, it aims to deliver safe, effective, and accessible mental health care worldwide by combining drug formulation technologies with a scalable digital prescription care platform.